TY - T1的MRI影像学报告的验证在儿科,根据2017年麦当劳标准:丹麦全国多中心队列研究(p13 - 4.007) JF -神经学乔-神经学六世- 98 - 18补充SP - 109 AU -马格努斯Boesen AU -安妮卡Langkilde盟Jurgita Ilginiene AU -梅林达Magyari盟Morten Blinke首页nberg Y1 - 2022/05/03 UR - //www.ez-admanager.com/content/98/18_Supplement/109.abstract N2 -目的:验证MS-specific结果通过比较MS-specific女士在儿科医院核磁共振报告结果在核磁共振报告MS-specific二次核磁共振检查的结果。背景:核磁共振成像允许示范传播在时间和空间上的第一个脱髓鞘事件。但是,没有女士儿科研究调查的有效性MS-specific结果中描述MRI影像学报告,临床医生依靠使MS诊断和评估女士治疗。设计/方法:高级顾问和居民神经学家MS-specific结果提取数据从核磁共振报告在基线和随访患儿发病女士在丹麦在2008 - 15。黄金标准是两个专家神经放射的二次核磁共振检查。我们估计百分比协议和Kappa值通过比较数据从医院核磁共振报告(我们想测试)和二次核磁共振检查的结果(我们的黄金标准)。结果:与女士55岁儿童,我们包括44基线和48后续核磁共振成像。在MS发病年龄中位数是16.3年(范围9.2 - -17.9)。协议之间的核磁共振报告和二级MS-specific结果MRI检查范围68% - -100%;协议是更高的MRI结果在场的时候。Kappa值范围从0.42(“温和”)到1.00(“优秀”)。Kappa的实现基线MRI麦当劳2017标准是0.60,和0.53随访MRI。Kappa后续新病变MRI是0.41。Conclusions: Agreement was moderate to good for most MS-specific outcomes between MS neurologists’ data extraction from hospital MRI radiological reports compared with neuroradiologists’ secondary MRI reviews. The agreement was moderate for both fulfilling the McDonald 2017 criteria and acquiring a new lesion on follow-up MRI. We recommend structured MRI reporting in children suspected of acquired demyelinating syndromes to increase validity of hospital MRI reports and clinical use.Disclosure: Dr. Spangsberg Boesen has nothing to disclose. Mrs. Ilginiene has nothing to disclose. Dr. Magyari has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Magyari has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Magyari has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Magyari has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Magyari has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Dr. Magyari has received research support from The Danish MS Society. The institution of Dr. Magyari has received research support from Biogen. The institution of Dr. Magyari has received research support from Novartis. The institution of Dr. Magyari has received research support from Roche. The institution of Dr. Magyari has received research support from Merck. The institution of Dr. Magyari has received research support from Sanofi. The institution of Morten Bjorn Blinkenberg, MD, PhD has received research support from Danish MS Society. ER -